Log In
BCIQ
Print this Print this
 

romosozumab (AMG 785, CDP7851)

Also known as: anti-sclerostin antibody

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionHumanized mAb against sclerostin
Molecular Target Sclerostin
Mechanism of ActionBinds sclerostin; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentRegistration
Standard IndicationOsteoporosis
Indication DetailsTreat bone loss in postmenopausal women; Treat osteoporosis; Treat osteoporosis in men; Treat osteoporosis in postmenopausal women; Treat osteoporosis in postmenopausal women at increased risk of fracture
Regulatory Designation
PartnerAstellas Pharma Inc.;
UCB Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/03/2013

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today